Business
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant
About this update from Dyadic International, Inc.
[{"type":"text","content":"Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbuminOngoing development of a robust pipeline of non-pharmaceutical recombinant product candidates such as alpha-lactalbumin, transferrin, DNASE-1, and several potential biofuels and other enzymes utilizing the Dapibus™ platform technology Animal Health Provided samples of the C1-produced recombinant ferritin nanoparticle H5 Clade 2.3.3.4.b A/Astrakhan avian influenza ‘Bird Flu’ antigen to multiple parties for evaluation and potential use in poultry and cattle vaccinesInitiated analysis of additional targets for expanded collaboration with Phibro/Abic to develop vaccines and treatments for livestock animal diseases Human Health C1-produced adjuvanted H5 Clade 2.3.3.4.b A/Astrakhan recombinant ferritin nanoparticle vaccine candidate demonstrated a strong immune response against the H5 Astrakhan avian influenza ‘Bird Flu’ in animal studiesSuccessfully expressed H1N1 influenza antigen completing Dyadic’s initial objectives for the collaboration with the Vaccine and Immunotherapy Center at Massachusetts General HospitalMultiple applications submitted for grant funding from leading Non-Governmental Organization in collaboration with Fondazione Biotecnopolo di Siena and other partners for a variety of vaccine antigens Corporate Cash and investment grade securities of $10.1 million as of June 30, 2024Financial results and business update conference call scheduled for 5:00 p.m. ET today JUPITER, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced its financial results for the second quarter of 2024 and highlighted recent Company progress. \"This quarter, we saw the positive impact of our business strategy, which focuses on near-term non-pharmaceutical applications and mid- to long-term applications in animal and human health for o...